Results 51 to 60 of about 4,786,755 (237)

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis [PDF]

, 2021
Background Systemic immunoglobulin light-chain (AL) amyloidosis is characterized by deposition of amyloid fibrils of light chains produced by clonal CD38+ plasma cells.
Minnema, M. C., Hungria, Waxman, A. J., Suzuki, K., Bumma, N., Venner, C. P., Shimazaki, C., Gatt, M. E., Wong, S. W., Crusoe, E., Song, K., Rosenzweig, M., Jaccard, A., Qin, X., Hansen, T., Schonland, S., Jamroziak, K., Kim, J-S, Roeloffzen, W., Lee, H. C., Gibbs, S., Libby, E., Ahmadi, T., Dimopoulos, M. A., Tran, N. P., Weiss, B. M., Vermeulen, J., Sanchorawala, [No Value], Kim, K., Schecter, J. M., Lam, S., Mollee, P., Merlini, G., Goodman, S. A., Tromp, B., Kwok, F., Comenzo, R. L., Vasey, S. Y., Manier, S., Beksac, M., Zhuang, S. H., Palladini, G., Huart, A., Roeloffzen, W.; id_orcid, Lu, J., Valent, J., Cibeira, M. T., Zonder, J. A., Wechalekar, A. D., Bhutani, D., Kastritis, E.   +50 more
core   +2 more sources

Syndrome in Question [PDF]

Anais Brasileiros de Dermatologia, 2015
Immunoglobulin light chain amyloidosis is the most common acquired systemic amyloidosis. Its presentation is often insidious and progressive, which may delay diagnosis.
Han MA, Meilan Chen, Juan Li, Ying Li, Shu Qiu   +4 more
doaj   +1 more source

Cardiac amyloidosis in a kidney transplant recipient [PDF]

Journal of Nephropathology
Systemic amyloidosis is a collection of diseases caused by the deposition of protein fibrils in organ tissues, leading to significant morbidity. Cardiac amyloidosis, a rare and debilitating condition, can affect any organ in the body.
Bahareh Marghoob, Mohammad Hassan Fallahkohan   +1 more
doaj   +1 more source

Misdiagnosis of hereditary amyloidosis as AL (Primary) amyloidosis [PDF]

, 2002
Background: Hereditary, autosomal dominant amyloidosis, caused by mutations in the genes encoding transthyretin, fibrinogen A -chain, lysozyme, or apolipoprotein A-I, is thought to be extremely rare and is not routinely included in the differential ...
Booth, D.R., Gilbertson, J.A., Hawkins, P.N., Booth, S.E., Lachmann, H.J., Gillmore, J.D., Bybee, A., Pepys, M.B.   +7 more
core  

The VHL tumor suppressor at the crossroad of protein folding, aggregation, and cancer

Molecular Oncology, EarlyView.
Mutations, environmental stress, and chaperone dysfunction can destabilize pVHL, promoting its conversion from the native folded state into amyloid‐like assemblies. This transition may contribute to protein storage, cell dormancy, survival, and drug resistance.
Lara Abad, Silvio Carlo Ermanno Tosatto, Emanuela Leonardi   +2 more
wiley   +1 more source

Amyloidosis: a case series and review of the literature

Journal of Medical Case Reports, 2023
Background Systemic amyloidosis is group of disorders characterized by the accumulation of insoluble proteins in tissues. The most common form of systemic amyloidosis is light chain amyloidosis, which results from the accumulation of misfolded ...
Justin B. Senecal, Romel Abou-Akl, Pat Allevato, Ian Mazzetti, Caroline Hamm, Richa Parikh, Indryas Woldie   +6 more
doaj   +1 more source

Light chain amyloidosis: the heart of the problem

Haematologica, 2013
In this issue of Haematologica, Dinner et al. report the outcome of a pilot study of an oral regimen of lenalidomide in combination with dexamethasone and low-dose melphalan in 25 patients with light chain amyloidosis (AL), most of them with cardiac involvement.[1][1] The treatment proved to ...
MERLINI, GIAMPAOLO, PALLADINI, GIOVANNI
openaire   +4 more sources

Systemic amyloidosis in England: an epidemiological study. [PDF]

, 2013
Epidemiological studies of systemic amyloidosis are scarce and the burden of disease in England has not previously been estimated. In 1999, the National Health Service commissioned the National Amyloidosis Centre (NAC) to provide a national clinical ...
Smith, CJ, Banypersad, SM, Whelan, CJ, Venner, CP, Dungu, J, Pinney, JH, Lachmann, HJ, Taube, JB, Gillmore, JD, Gibbs, SD, Hawkins, PN, Wechalekar, AD   +11 more
core  

IgM-Related Immunoglobulin Light Chain (AL) Amyloidosis

, 2022
Waldenström macroglobulinemia (WM) is a rare lymphoplasmacytic disorder characterized by an IgM paraprotein. The clinical presentation of WM varies and can include common manifestations such as anemia and hyperviscosity, in addition to less common ...
Steven P. Treon, Jorge J. Castillo, Andrew R. Branagan, Shayna Sarosiek   +3 more
core   +1 more source

Predictive Ability of Plasma p‐tau217 for β‐Amyloid Status: A Prospective Multicenter Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Plasma tau phosphorylated at threonine 217 (p‐tau217) measured with fully automated platforms has shown high accuracy for Alzheimer's disease (AD) diagnosis, but real‐world multicenter data remain limited. We aimed to validate the diagnostic performance of p‐tau217 for identifying AD pathology in a real‐world multicenter cohort ...
Miquel Massons, Nuria Guillen, Jordi Sarto, Neus Falgàs, Sergi Borrego‐Écija, Diana Esteller‐Gauxax, Magda Castellví, Adrià Tort‐Merino, Agnès Pérez‐Millan, Anna Antonell, Josep M. Augè Fradera, Gerard Piñol, Iolanda Riba, Anna Carnes‐Vendrell, Marta Cullell, Maria Teresa Osuna, Lorena Bajo, Teresa Romero, Eva Bonjoch, Joan Bello, Susana Fernández, Marta Balagué, Isabel Gómez‐Ruiz, Anuncia Boltes, Claustre Pont, Raquel Cuevas, Sara Carrillo, Laura Iglesias, Teresa Maria Casadevall Codina, Lorena Grau Guinea, Fernando Jose Espada, Raquel Sánchez‐Valle, Mircea Balasa, Albert Lladó   +33 more
wiley   +1 more source